Dear Reader, Until tomorrow, we're sharing an urgent message about the Melt-Up. Over the coming weeks and months, I expect one sector of the market could skyrocket… sending certain stocks up 100% or more. Biotech. The fact is, you could realistically double your money before this Melt-Up is over if you own the best small biotech companies. That's why, until tomorrow, November 19th, I urge you to have a look at our research firm's #1 biotech opportunity right now. It details a company whose newest breakthrough could be approved beginning December 31st. Approval could send the stock soaring 200%. In short, this little-known company owns a cancer device we've waited 17 years for… and which could treat 50% of all cancer patients worldwide. When approval comes through – the stock could double very quickly… as we've seen many times before in this business. For example… Kite Pharma (KITE) is up 300% this year… after the FDA approved its first-ever gene therapy drug, Kymriah.Clovis (CLVS) is up 111% this year after getting approval for their ovarian cancer drug, Rubraca. That's why beginning soon… our top biotech pick could soar by hundreds of percent on news of approval for its new cancer device. But for the biggest gain, you must get in BEFORE approval comes through. So if you're interested, I urge you to get in by tomorrow. After tomorrow, November 19th, we're removing this message from circulation, and you'll be too late for it. You can get this offer here, until tomorrow. Regards, Steve Sjuggerud
Senior Analyst
Stansberry Research P.S. Again, this opportunity expires tomorrow. Until then – we'll also show you how to claim a free ebook on this topic. | 